Vitarka Therapeutics appoints Dr John Beadle as Chairman of the Board

London, 27 November 2024: Vitarka Therapeutics Ltd, the EndoPore® cancer therapeutics company, today announced the appointment of Dr John Beadle as the new Chairman of the Board. Vitarka is an innovative biotechnology company developing EndoPore®, a highly selective two-stage tumour-targeted technology with safe and efficient cytosolic delivery of highly potent payloads.

Dr Vineeta Tripathi, Founder and CEO of Vitarka Therapeutics said:

I am very pleased to announce today that John Beadle has joined Vitarka as our Chairman. John brings a wealth of experience in early-stage biotech businesses and has overseen the progression of multiple novel cancer therapies into clinical trials. This appointment strengthens our Board and supports the progression of our lead therapeutic asset into the clinic.

Dr John Beadle said:

I am delighted to join Vitarka as Chairman at this exciting time. I have been impressed by the energetic and experienced Vitarka team and by the impressive pre-clinical data already generated using the EndoPore platform in a range of hard to treat cancers. I look forward to helping Vitarka take this technology into clinical trials for the benefit of patients with cancer.

Dr Beadle is an accomplished entrepreneurial physician with a track record as a CEO, Chairman, and leader of innovative therapeutics companies. He has co-founded and grown several biotechnology companies focused on Advanced Therapy Medicinal Products (ATMP), including nucleotide-based vaccines, gene therapies, and cell therapies. His previous positions include Founding Chief Executive Officer of PsiOxus; Co-founder and Chief Medical Officer of PowderMed; Entrepreneur in Residence at Imperial College London; Vaccine Site Head at Pfizer; and VP of Global Medical Operations at GlaxoSmithKline.